Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells

International Journal of Cancer

Volumn 124, Issue 2, 2009, Pages 358-366

  Wehner, Rebekka ^a   Löbel, Bärbel ^a   Bornhäuser, Martin ^a   Schäkel, Knut ^a   Cartellieri, Marc ^a   Bachmann, Michael ^a   Rieber, Ernst Peter ^a   Schmitz, Marc ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Dendritic cells; NK cells; Tumor immunity

Indexed keywords

CD69 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; SLANDC; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 6 SULFO LACNAC; 6-SULFO-LACNAC; AMINOSUGAR; CYTOKINE; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LEUKEMIA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; TH1 CELL; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL STRAIN K 562; CYTOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONONUCLEAR CELL;

AMINO SUGARS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CYTOKINES; DENDRITIC CELLS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58249088470     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23962     Document Type: Article

References (40)

1. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
2. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-67.
3. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449:419-26.
4. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
5. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007;117:1195-203.
6. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
7. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, Vieweg J, Gilboa E. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6:1011-17.
8. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
9. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
10. Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
11. Wierecky J, Müller MR, Wirths S, Halder-Oehler E, Dörfel D, Schmidt SM, Häntschel M, Brugger W, Schröder S, Horger MS, Kanz L, Brossart P. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:5910-8.
12. Moretta A. The dialogue between human natural killer cells and dendritic cells. Curr Opin Immunol 2005;17:306-11.
13. Ghiringhelli F, Apetoh L, Housseau F, Kroemer G, Zitvogel L. Links between innate and cognate tumor immunity. Curr Opin Immunol 2007;19:224-31.
14. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006;20:123-37.
15. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
16. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-11.
17. Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008;118:1165-75.
18. Nishioka Y, Nishimura N, Suzuki Y, Sone S. Human monocyte-derived and CD83(+) blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur J Immunol 2001;31:2633-41.
19. Amakata Y, Fujiyama Y, Andoh A, Hodohara K, Bamba T. Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes. Clin Exp Immunol 2001; 124:214-22.
20. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Müunz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343-51.
21. Yu Y, Hagihara M, Ando K, Gansuvd B, Matsuzawa H, Tsuchiya T, Ueda Y, Inoue H, Hotta T, Kato S. Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol 2001;166:1590-600.
22. Piccioli D, Sbrana S, Melandri E, Valiante NM. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002;195:335-41.
23. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-33.
24. Schäkel K, Mayer E, Federle C, Schmitz M, Riethmüller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol 1998;28:4084-93.
25. Schäkel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber E. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002;17:289-301.
26. Schäkel K, von Kietzell M, Huansel A, Ebling A, Schulze L, Haase M, Semmler C, Sarfati M, Barclay AN, Randolph GJ, Meurer M, Rieber EP. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 2006;24:767-77.
27. Schmitz M, Zhao S, Schäkel K, Bornhäuser M, Ockert D, Rieber EP. Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. Blood 2002;100:1502-04.
28. Schmitz M, Zhao S, Deuse Y, Schäkel K, Wehner R, Wöhner H, Hölig K, Wienforth F, Kiessling A, Bornhäuser M, Temme A, Rieger MA, et al. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of. NK cell-mediated cytotoxicity. J Immunol 2005;174:4127-34.
29. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
30. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007;13:4677-85.
31. Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, Ryffel B, Cambi A, Figdor C, Vainchenker W, Galy A, Caignard A, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004;104:3267-75.
32. Ferlazzo G, Pack M, Thomas D, Paludan C, Schmid D, Strowig T, Bougras G, Muller WA, Moretta L, Muunz C. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci USA 2004; 101:16606-11.
33. Münz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 2005;105:266-73.
34. Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, Trinchieri G. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005;174:727-34.
35. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L, Moretta A, Thiel A. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. Eur J Immunol 2005;35:2452-8.
36. Hanabuchi S, Watanabe N, Wang YH, Wang YH, Ito T, Shaw J, Cao W, Qin FX, Liu YJ. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 2006;107:3617-23.
37. Semino C, Angelini G, Poggi A, Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 2005;106:609-16.
38. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aricò M, Moretta L, Moretta A. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005;106:566-71.
39. Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, Tarner IH, Engleman EG, Söderstruom K. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 2007;110:2484-93.
40. Della Chiesa M, Romagnani C, Thiel A, Moretta L, Moretta A. Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Blood 2006;108:3851-8.